PMID: 11331435May 2, 2001Paper

Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia

The Oncologist
S L Soignet

Abstract

Acute promyelocytic leukemia (APL) has unique clinical, cytogenetic, and molecular features and is one of the most potentially curable human malignancies. The current standard treatment given to patients with newly diagnosed APL consists of all-trans retinoic acid and anthracycline-based cytotoxic chemotherapy, which is highly effective for remission induction. However, despite the potential for cure with existing treatments, approximately 20%-30% of patients relapse and require salvage therapy. Reports of the safety and efficacy of arsenic trioxide from centers in China led to a pivotal trial of this agent in the United States for patients with relapsed APL. In an initial pilot study, 11 of 12 patients experienced a complete response, and a subsequent multicenter trial confirmed the efficacy and safety of arsenic trioxide for remission induction in this patient population. Additional trials are under way to evaluate the use of this agent alone or as part of a chemotherapy regimen for consolidation and maintenance of patients with APL.

References

Dec 15, 1977·International Journal of Cancer. Journal International Du Cancer·J D RowleyD Potter
Aug 25, 1992·Annals of Internal Medicine·S R FrankelR P Warrell
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·T R BreitmanS J Collins
Feb 15, 1994·Annals of Internal Medicine·S R FrankelR P Warrell
Jul 15, 1993·The New England Journal of Medicine·R P WarrellL Degos
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·J ZhuH de Thé
Oct 9, 1997·The New England Journal of Medicine·M S TallmanP H Wiernik
Nov 5, 1998·The New England Journal of Medicine·S L SoignetR P Warrell
Jan 19, 1999·Cancer Treatment and Research·J L Slack, R E Gallagher
Apr 1, 1999·The New England Journal of Medicine·J S MenellK A Hajjar
May 18, 1999·Journal of the National Cancer Institute·G Kroemer, H de Thé
Jun 28, 2000·Annals of Hematology·J L Slack, M E Rusiniak

❮ Previous
Next ❯

Citations

Mar 12, 2013·European Journal of Pharmacology·Masafumi KumazakiAkio Fujimura
Dec 4, 2003·Mutation Research·Jia-Ran GurrKun-Yan Jan
Mar 26, 2004·Regulatory Toxicology and Pharmacology : RTP·Joyce S TsujiGene C Hook
Jan 30, 2002·Drug Discovery Today·Kathryn Senior
Aug 26, 2003·Best Practice & Research. Clinical Haematology·Elihu H Estey
Aug 26, 2003·Best Practice & Research. Clinical Haematology·Francesco Lo-CocoDaniela Diverio
Jan 27, 2007·Cardiovascular Ultrasound·Maurizio GalderisiOreste de Divitiis
Jun 8, 2014·Best Practice & Research. Clinical Haematology·Matthew A KutnyJames H Feusner
Jun 8, 2014·Best Practice & Research. Clinical Haematology·Harry J IlandJohn F Seymour
Mar 7, 2002·Cancer Practice·M S Lam, R J Ignoffo
Dec 18, 2007·Cardiovascular Toxicology·Enrico VizzardiLivio Dei Cas
Dec 20, 2003·Blood Reviews·Mark R Litzow
Aug 5, 2003·Current Oncology Reports·Joseph G Jurcic
Jan 31, 2008·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Mengchang WangPengbo Liu
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin D FloydMichael C Perry
Oct 29, 2002·Leukemia & Lymphoma·T Bachleitner-HofmannH Gisslinger
Feb 12, 2004·British Journal of Haematology·Dilip UnnikrishnanPeter H Wiernik
Feb 22, 2005·The Journal of Pharmacology and Experimental Therapeutics·Geniece McCollumMichael J McCabe
Oct 12, 2005·International Journal of Cancer. Journal International Du Cancer·Liqiong LuoXueying Sun
Jan 14, 2003·Hematological Oncology
Jan 18, 2006·Annual Review of Medicine·Edward T H Yeh
Apr 11, 2013·Cardiology·I BurazorY Adler
Jul 11, 2006·Cancer Science·Bing LiuXueying Sun
Jul 28, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Guifen HeLong Yu
Jan 22, 2017·American Journal of Clinical Pathology·Vanessa J DaytonMichael A Linden
Nov 19, 2002·Clinical Journal of Oncology Nursing·Jami MayorgaKarel A Dicke

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.